Compare › tirzepatide vs retatrutide
tirzepatide vs retatrutide
tirzepatide is approved in the US; retatrutide is not, and is still investigational. That is the largest single difference between them and it is easy to lose in a feature comparison. tirzepatide has 139 trials on file here and retatrutide 14, which is a rough measure of how far each programme has been pushed.
A side-by-side of what the public record holds on each: regulatory status in the US and EU, how much trial work is running, and which conditions each is being studied in. No efficacy comparison: head-to-head claims belong to the trials that made them, not to us.
| tirzepatide | retatrutide | |
|---|---|---|
| Status | marketed | phase3 |
| Target | GIP/GLP-1 | GIP/GLP-1/glucagon |
| Route | SC | SC |
| Sponsor | Eli Lilly | Eli Lilly |
| US brand names | MOUNJARO, MOUNJARO (AUTOINJECTOR), MOUNJARO KWIKPEN, ZEPBOUND, ZEPBOUND (AUTOINJECTOR), ZEPBOUND KWIKPEN | — |
| First FDA approval | 2022-05-13 | Not approved |
| EU authorisation | Mounjaro | Not authorised |
| FDA actions on file | 27 | 0 |
| Active trials | 99 | 7 |
| Active phase 3 | 20 | 6 |
| Participants enrolled | 43,561 | 12,699 |
| Results scheduled | 34 | 7 |
| Supply records | 0 | 0 |
Where they are being studied
Both: Cardiovascular disease; Chronic kidney disease; Obesity & overweight; Obstructive sleep apnea; Osteoarthritis; Type 2 diabetes
tirzepatide only: Alcohol use disorder; Atrial fibrillation; Cancer; Diabetes (unspecified); Heart failure; Hypertension; MASH / NAFLD; Metabolic syndrome; Polycystic ovary syndrome; Prediabetes; Psychiatric conditions; Substance use; Type 1 diabetes